GlassScriptPhysician profile
Tracey C Wallace
NPI 1265475206
$3,335.16
in general payments reported to CMS, 2019-2025
23 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $684 · 2021: $762 · 2022: $396 · 2023: $400 · 2024: $409 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $675.83 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $367.92 | 2020-2024 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $265.27 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.11 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $250.56 | 2019-2025 | Lagevrio |
| Glaxosmithkline, LLC. | $211.16 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $197.49 | 2021-2025 | Vraylar |
| Genentech USA, INC. | $195.24 | 2019-2021 | |
| Amgen INC. | $128.43 | 2020-2025 | Krystexxa, Repatha |
| Kowa Pharmaceuticals America, INC. | $101.86 | 2019-2022 | |
| Dynavax Technologies Corporation | $101.82 | 2020-2024 | Heplisav-B |
| Lilly USA, LLC | $101.47 | 2020-2024 | Mounjaro |
| Exact Sciences Corporation | $96.85 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $81.08 | 2020-2024 | |
| Astellas Pharma US INC | $76.52 | 2023-2024 | Veozah |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $68.83 | 2020-2023 | Rexulti |
| Eisai INC. | $50.57 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $30.98 | 2019 | |
| Neos Therapeutics, LP | $19.49 | 2023 | Adzenys Xr-Odt |
| Novartis Pharmaceuticals Corporation | $16.04 | 2023 | |
| Xeris Pharmaceuticals, INC. | $15.80 | 2024 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $14.75 | 2020 | |
| Sumitomo Pharma America, INC. | $13.09 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracey Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.